Synapse - Stephen Nimer

Results (121)

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

Journal Article

Kewalramani, T.; Zelenetz, A. D.; Teruya-Feldstein, J.; Hamlin, P.; Yahalom, J.; Horwitz, S.; Nimer, S. D.; Moskowitz, C. H.
British Journal of Haematology (2006)

Fulltext@MSK | Save

Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study

Journal Article

Kantarjlan, H.; Issa, J. P. J.; Rosenfeld, C. S.; Bennett, J. M.; Albitar, M.; DiPersio, J.; Klimek, V.; Slack, J.; De Castro, C.; Ravandi, F.; more...
Cancer (2006)

Fulltext@MSK | Save

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma

Journal Article

Hassoun, H.; Reich, L.; Klimek, V. M.; Dhodapkar, M.; Cohen, A.; Kewalramani, T.; Zimman, R.; Drake, L.; Riedel, E. R.; Hedvat, C. V.; more...
British Journal of Haematology (2006)

Fulltext@MSK | Save

Results of a phase I/II trial adding carmustine (300mg/m 2) to melphalan (200mg/m 2) in multiple myeloma patients undergoing autologous stem cell transplantation

Journal Article

Comenzo, R. L.; Hassoun, H.; Kewalramani, T.; Klimek, V.; Dhodapkar, M.; Reich, L.; Teruya-Feldstein, J.; Fleisher, M.; Filippa, D.; Nimer, S. D.
Leukemia (2006)

Fulltext@MSK | Save

Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-Cell lymphomas: Minimal benefit when analyzed by intent to treat

Meeting Abstract

Horwitz, S.; Moskowitz, C.; Kewalramani, T.; Hamlin, P.; Straus, D.; O'connor, O.; Noy, A.; Portlock, C.; Nimer, S.; Palomba, M. L.; more...
Blood (2005)

Fulltext@MSK | Save

The serum free light chain ratio after one or two cycles of treatment is highly predictive of the magnitude of final response in patients undergoing initial treatment for multiple myeloma

Meeting Abstract

Hassoun, H.; Reich, L.; Klimek, V. M.; Dhodapkar, M.; Cohen, A.; Kewalramani, T.; Riedel, E. R.; Hedvat, C. V.; Teruya-Feldstein, J.; Filippa, D. A.; more...
Blood (2005)

Fulltext@MSK | Save

Risk-adapted dosing of melphalan for systemic AL amyloidosis (AL) lowers treatment-related mortality: Early death but not post-3 month survival is linked to cardiac involvement

Meeting Abstract

Comenzo, R. L.; Zhou, P.; Hassoun, H.; Kewalramani, T.; Klimek, V.; Cohen, A. D.; Ferrand, S. K.; Dhodapkar, M.; Feldstein, J. T.; Fleisher, M.; more...
Blood (2005)

Fulltext@MSK | Save

Adjuvant dexamethasone (D)+/- thalidomide (T) improves hematologic and organ responses after risk-adapted high-dose melphalan with autologous stem cell transplant (SCT) for patients with systemic AL amyloidosis (AL)

Meeting Abstract

Cohen, A. D.; Zhou, P.; Reich, L.; Hassoun, H.; Teruya-Feldstein, J.; Filippa, D. A.; Fleisher, M.; Nimer, S. D.; Comenzo, R. L.
Blood (2005)

Fulltext@MSK | Save

Induction of remission prior to transplantation improves the disease-free survival (DFS) of patients with advanced myelodysplastic syndromes (MDS) treated with myeloablative T-cell depleted (TCD) stem cell transplants (SCT) from HLA identical siblings